Global Allergic Rhinitis Drugs Market 2019-2023| Evolving Opportunities with ALK-Abelló & GlaxoSmithKline |Technavio
LONDON--(BUSINESS WIRE)--Nov 22, 2019--
The global allergic rhinitis drugs market size is poised to grow by USD 2.25 billion during 2019-2023, according to a new report by Technavio, progressing at a CAGR of close to 4% during the forecast period. Request Free Sample Pages
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191122005324/en/
Technavio has announced its latest market research report titled global allergic rhinitis drugs market 2019-2023 (Graphic: Business Wire)
Read the 127-page research report with TOC on “Allergic Rhinitis Drugs Market Analysis Report by Product (Antihistamines, Intranasal corticosteroids, Immunotherapies, and Others) and Geography (Americas, APAC, and EMEA) 2019-2023.″
The market is driven by the increasing awareness about allergic rhinitis. Also, the increasing demand for over-the-counter medicines is anticipated to further boost the growth of the allergic rhinitis drugs market.
With growing prevalence of allergic rhinitis worldwide, there has been a significant rise in the number of initiatives to increase the awareness about the disease. For instance, the Asthma and Allergy Foundation of America observes April as the allergic rhinitis awareness month. The organization conducts several programs such as online events and conferences. The increasing awareness about allergic rhinitis and improves patient access to the treatment in the early stages of the disease. It also increases the chances of accurate diagnosis by physicians.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Four Allergic Rhinitis Drugs Companies:
ALK-Abelló is engaged in the development and commercialization of allergy treatment products. The company’s key offerings include ACARIZAX, and GRAZAX. ACARIZAX is used for the treatment of house dust mite allergy and GRAZAX is used to treat grass pollen allergies.
GlaxoSmithKline has business operations under various segments, which include pharmaceutical, vaccines, and consumer healthcare. The company’s key offerings include Avamys/Veramyst, which is a synthetic corticosteroid used for the treatment of allergic rhinitis.
Merck operates its business through various segments, namely pharmaceutical, animal health, healthcare services, and alliances. The company offers Singulair and Nasonex for the treatment of allergic rhinitis. Singulair is an oral medicine used to reduce the symptoms of allergic rhinitis, while Nasonex is an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms.
Sanofi is engaged in the development of drugs under various segments such as cardiovascular and metabolism, oncology, immunology and inflammation, neurology, gene therapy, infectious disease, and rare disease therapeutic areas. The company’s key offerings in the market include Nasacort, and Allegra.
Stallergenes Greer is engaged in the development and commercialization of allergy immunotherapy products and services. The company’s key offerings for the treatment of allergic rhinitis include ORALAIR, ACTAIR, and Staloral.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform
Allergic Rhinitis Drugs Product Outlook (Revenue, USD Million, 2019-2023)
Allergic Rhinitis Drugs Regional Outlook (Revenue, USD Million, 2019-2023)
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.Request a free sample report
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191122005324/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 11/22/2019 02:00 PM/DISC: 11/22/2019 02:00 PM